Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome

International Journal of Dermatology

Volumn 42, Issue 2, 2003, Pages 116-122

  Pielop, J A ^a   Brownell, I ^a   Duvic, M ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b University of Texas Health Science Center at Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE;

AGED; ARTICLE; CANCER RISK; CLINICAL ARTICLE; DATA BASE; DISEASE ASSOCIATION; DYSPLASTIC NEVUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MALE; MELANOMA; METASTASIS; MYCOSIS FUNGOIDES; ADULT; CASE REPORT; FACTUAL DATABASE; FEMALE; MIDDLE AGED; MULTIPLE CANCER; REGISTER; SKIN TUMOR;

ADULT; AGED; DATABASES, FACTUAL; DYSPLASTIC NEVUS SYNDROME; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASMS, MULTIPLE PRIMARY; REGISTRIES; SKIN NEOPLASMS;

EID: 0038542808     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1046/j.1365-4362.2003.01697.x     Document Type: Article

References (29)

1. Kantor AF, Curtis RE, Vonderheid EC, Van Scott EJ, Fraumeni JF Jr. Risk of second malignancy after cutaneous T cell lymphoma. Cancer 1989; 63: 1611-1615.
2. Reseghetti A, Tribbia G, Locati F, Naldi L, Marchesi L. Cutaneous malignant melanoma appearing during photochemotherapy of mycosis fungoides. Dermatology 1994; 189: 75-77.
3. Soong V, Lee PC, Kissel RB, Sams WM Jr, Tyring SK. Fatal malignant melanoma associated with a completely regressed primary melanoma in a patient with cutaneous T-cell lymphoma. Arch Dermatol 1987; 123: 1270-1171.
4. Flindt-Hansen H, Brandrup F. Malignant melanoma associated with mycosis fungoides. Derniatologica 1984; 169: 167-168.
5. Amichai B, Grunwald MH, Goldstein J, Finkelstein E, Halevy S. Small malignant melanoma in patients with mycosis fungoides. J Eur Acad Dermatol Venereol 1998; 11: 155-157.
6. Licata AG, Wilson LD, Braverman IM, Feldman AM, Kacinski BM. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. Arch Dermatol 1995; 131: 432-435.
7. DuVivier A, Vonderheid EC, Van Scott EJ, Urbach F. Mycosis fungoides, nitrogen mustard and skin cancer. Br J Dermatol 1978; 99: 61-64.
8. Abel EA, Sendagorta E, Hoppe RT. Cutaneous malignancies and metastatic squamous cell carcinoma following topical therapies for mycosis fungoides. J Am Acad Dermatol 1986; 14: 1029-1038.
9. Smoller BR, Marcus R. Risk of secondary cutaneous malignancies in patients with long-standing mycosis fungoides. J Am Acad Dermatol 1994; 30: 201-204.
10. Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol 1989; 20: 416-428.
11. Gupta AK, Stern RS, Swanson NA, Anderson TF. Cutaneous melanomas in patients treated with psoralens plus ultraviolet A: a case report and the experience of the PUVA Follow-up Study. J Am Acad Dermatol 1988; 19: 67-76.
12. Stern, RS, Nichols KT, Vakeva, LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). New Engl J Med 1997; 336: 1041-1045.
13. Reddy VB, Ramsay D, Garcia JA, Kamino H. Atypical cutaneous changes after topical nitrogen mustard treatment in patients with mycosis fungoides. Am J Dermatolpathol 1996; 18: 19-23.
14. Heald P, Yan S-L, Edelson R. Profound deficiency in normal circulating T cells in erythrodermic cutaneous T-cell lymphoma. Arch Dermatol 1994; 130: 198-203.
15. Lee B-N, Duvic M, Tang C-K, Bueso-Ramos, C, Estrov, Z, Reuben JM. Dysregulated synthesis of intracellular type I and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma. Clin Diag Laboratory Immunol 1999; 6: 79-84.
16. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40: 177-186.
17. Aboulafia DM. Malignant melanoma in an HIV-infected man: a case report and literature review. Cancer Invest 1998; 16: 217-224.
18. Jackow CM, McHam, JB, Friss A, Alvear J, Reveille JR, Duvic M. HLA-DR5 and DQBi*03 class II alleles are associated with cutaneous T-cell lymphoma. J Invest Dermatol 1996; 107: 373-376.
19. Lee JE, Lu M, Mansfield PF, Platsoucas CD, Reveille JD, Ross MI. Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer stage I or II. Cancer 1996; 78: 758-763.
20. Greene MH, Clark WH Jr, Tucker MA, Draemer KH, Elder DE, Fraser MC. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Int Med 1985; 102: 458-465.
21. Newton Bishop JA, Wachsmuth RC, Harland M, et al. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J Invest Dermatol 2000; 114: 28-33.
22. Monzon J, Liu L, Brill H, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998; 338: 879-887.
23. Crijns MB, Vink J, Van Hees CL, Bergman W, Vermeer BJ. Dysplastic nevi: occurrence in first- and second-degree relatives of patients with "sporadic" dysplastic nevus syndrome. Arch Dermatol 1991; 127: 1346-1351.
24. Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A (p16)/ARF tumor suppressors. J Am Acad Dermatol 2000; 42: 705-722.
25. Park WE, Vortmeyer AO, Pack S, et al. Allelic deletion at chromosome 9p21 (p16) and 17p13 (p53) in microdissected sporadic dysplastic nevus. Hum Pathol 1998; 29: 127-130.
26. INK4a in mycosis fungoides. Arch Dermatol Res 1999; 291: 207-211.
27. INK4a gene alterations are frequent in lesions of mycosis fungoides. Am J Pathol 2000; 156: 1565-1572.
28. Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 1989; 20: 395-407.
29. Russell-Jones R. Interferon-alpha therapy for melanoma. Clin Exp Dermatol 2000; 25: 1-6.